RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and ...

Fintel reports that on January 6, 2026, Wells Fargo upgraded their outlook for O-I Glass (NYSE:OI) from Equal-Weight to ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's Anatomy." Or maybe the words "osteogenesis imperfecta," or "OI," don't ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Osteogenesis imperfecta (OI) is a heterogeneous group of genetic disorders that affect connective tissue integrity. The hallmark of OI is bone fragility, although other manifestations, which include ...

Actress Melanie Watson Bernhardt, known for her role on Diff'rent Strokes, passed away at 57. Despite living with ...

A new study led by Baylor College of Medicine identifies an underlying mechanism of pathogenesis for osteogenesis imperfecta (OI) in human bone. The report, published in the Journal of Clinical ...

Brazilian telco Oi has finalized the sale of its fiber optic business to V.tal for R$5.71 billion ($980 million). Valor International reports that the deal will be carried out through the settlement ...

What Is Brittle Bone Disease? Brittle bone disease, also called osteogenesis imperfecta, is a genetic connective tissue disorder that is preset at birth and lasts for life. It causes fragile bones ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...